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In the last decade, many nonsteroidal sub-
stances have been shown to bind to the
human estrogen receptor α (ERα), hereby
mimicking the effects of the natural estrogen
17β-estradiol (1). Xenoestrogens, such as cer-
tain pesticides and industrial chemicals, have
been held responsible for disrupting the nor-
mal endocrine function in animals, thereby
causing reproductive disorders and abnormal-
ities in wildlife. It has been hypothesized that
these chemicals are responsible for increases in
reproductive tract abnormalities and low
sperm counts in men, and increases in breast
cancer in women (2–5). A second class of
chemicals that interact with the estrogen
receptor is phytoestrogens, naturally occurring
compounds in plants. Phytoestrogens can be
divided in four chemical categories depending
on their chemical structure: coumestans,
resorcyclic acid lactones, isoflavones, and
dihydroxychalcones (6). 
Nutritional and health research is focus-
ing on isoflavones. These molecules occur
predominantly as biologically inactive β-gly-
cosides (conjugated isoflavones) in soy (7).
After ingestion, the glycosides are hydrolyzed
in the large intestine by bacteria to release the
bioactive phytoestrogens (free isoflavones).
The gut microbiota play an important role in
the generation of biologically active
isoflavones, but at the same time these bioac-
tive compounds become inactive after further
bacterial fermentation, resulting in a loss of
their beneficial effects (8). Isoflavones are
now considered potential alternative thera-
pies for a range of hormone-dependent con-
ditions, including cancer, menopausal
symptoms, cardiovascular disease, and osteo-
porosis (9,10). The distinct biological effects
caused by phytoestrogens may be explained
by their ability to bind a second estrogen
receptor (ERβ), which has been discovered
recently. The tissue distribution and relative
ligand-binding affinities of the ERβ and ERα
differ, and this may help explain the selective
action of these compounds (11,12).
Much attention has been focused on the
development of screening strategies to iden-
tify and classify estrogenic substances. A bat-
tery of in vitro tests of different complexity
can be used to measure the estrogenic activity
of test chemicals. Animal cell-based and
yeast-based transactivation systems have been
used (13). One of the most widely applied in
vitro assays uses genetically modified yeast
strains that harbor an estrogen receptor
expression cassette and a reporter construct
(6,14,15). Interaction of an estrogenic sub-
stance with the estrogen receptor causes a
conformational change in the receptor,
enabling the estrogen–estrogen receptor com-
plex to bind to estrogen-responsive elements.
The latter are located upstream of the lacZ
reporter gene present on a reporter plasmid.
Incubation of these recombinant yeasts with
estrogenic chemicals triggers the expression
of β-galactosidase. Routledge and Sumpter
(16) have used such a recombinant yeast to
measure estrogenic activity by the conversion
of the chromogenic substance chlorophenol
red-β-D-galactopyranoside (CPRG) into
chlorophenol red by the action of the
reporter enzyme β-galactosidase. During vali-
dation of the Routledge and Sumpter assay
(RS assay), Vanderperren et al. (17) found
high blank values, especially after prolonged
incubation. A similar effect was observed
when higher cell densities were used in the
incubation vials compared to the cell densi-
ties used in the RS assay. These were the first
indications that CPRG or chlorophenol red
may possess estrogenic characteristics. During
additional experiments, Vanderperren et al.
(17) demonstrated dose-dependent estro-
genic effects in the RS assay starting from
CPRG concentrations of 165 µmol/L, which
is also the concentration used in the RS assay
as substrate for quantification of β-galactosi-
dase activity.
To prevent possible interference of
CPRG, we redesigned the RS assay. In a first
phase, the validity of the assay was verified
by testing a number of pure chemicals. In a
second phase, the modified assay was used
to detect the release of bioactive isoflavones
by a microbial suspension, cultured in a
simulator of the human intestinal microbial
ecosystem.
Materials and Methods
Chemicals. We purchased 17β-estradiol,
bisphenol A, methoxychlor, p,p´-DDT, and
the isoflavones genistein and daidzein from
Sigma (Bornem, Belgium). Plantech (Reading,
UK) supplied glycitein. Chemical structures
of the compounds are shown in Figure 1.
The compounds were dissolved in absolute
ethanol and stock solutions were kept at 4°C.
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Here we describe a redesigned protocol of the yeast estrogen screen developed by Routledge and
Sumpter. The redesigned test comprises two steps. First, a large amount of yeast with estrogenic
compounds is incubated for 24 hr. Subsequently, a mixture of cycloheximide and the chro-
mogenic substrate chlorophenol red-β-D-galactopyranoside (CPRG) is added. The cycloheximide
stops protein synthesis and allows for an end-point measurement of β-galactosidase activity gen-
erated during the first 24 hr. CPRG is converted to chlorophenol red and reflects β-galactosidase
activity, which is indicative of the estrogenic activity. The modifications shorten the duration of
the assay at least 1 day and avoid interference of the estrogenic CPRG or chlorophenol red. The
redesigned and the original protocol were used to study the estrogenic activity of bisphenol A,
methoxychlor, p,p´-DDT, and isoflavones (genistein, daidzein, and glycitein). Bisphenol A,
methoxychlor, and genistein triggered higher levels of β-galactosidase activity in the redesigned
protocol. Estrogenic activity of p,p´-DDT could only be demonstrated with the redesigned proto-
col. Glycitein and daidzein failed to give a response with both protocols. We also studied deconju-
gation of β-glycosidic isoflavones present in soygerm powder. Treatment of the soygerm powder
with β-glycosidase released isoflavones. The estrogenic response of the samples was confirmed
with the redesigned protocol and correlated with the amount of genistein present. The release of
isoflavones under conditions prevailing in the intestines was studied. Bacterial β-glycosidase pre-
sent in the large intestine released isoflavones, and moderate estrogenic activity could be demon-
strated. Key words: β-glycosidase, estrogen screen, gut microbiota, isoflavones. Environ Health
Perspect 109:691–697 (2001). [Online 29 June 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p691-697deboever/abstract.html
All other chemicals were obtained from
Sigma unless otherwise noted.
Recombinant yeast screen. Details of the
yeast estrogen screen and preparation of the
medium compounds have been described by
Routledge and Sumpter (16). The Genetics
Department at Glaxo (Glaxo Group
Research Ltd., Middlesex, UK) transformed
Saccharomyces cerevisiae with the human
ERα gene, together with expression plasmids
containing estrogen responsive elements and
the lacZ reporter gene (encoding the enzyme
β-galactosidase). The expression of β-galac-
tosidase is triggered by test chemicals, which
upon binding to the estrogen receptor
induce the conformational change necessary
for binding of the receptor/ligand dimer to
the estrogen-responsive elements. This β-
galactosidase activity is quantified by the
conversion of the chromogenic substrate
CPRG into chlorophenol red.
Standard assay procedure. Test chemicals
were serially diluted in absolute ethanol, and
10-µL aliquots of each concentration were
transferred to a microtiter plate and allowed
to evaporate. We thawed 125 µL of the
recombinant yeast stock stored at –70°C and
added it to 50 mL growth medium. The cul-
ture was incubated at 28°C until the cell den-
sity reached an absorbance of 1 at 620 nm.
Assay medium was prepared by the addition
of 2 mL of the overnight yeast culture to 50
mL growth medium supplemented with 0.5
mL 10 mg/L CPRG stock solution. Each
well of the microtiter plate was seeded with
200 µL assay medium (final absorbance at
620 nm was 0.02), and the plate was placed
in an incubator at 32°C. From day 3 on, we
checked the plates periodically for color
development and turbidity of the medium at
575 nm and 620 nm, respectively, using an
iEMS Reader/Dispenser MF (Labsystems
Benelux B.V., Brussels, Belgium).
Modified assay procedure. Similar to the
standard procedure, 125 µL of the yeast stock
was thawed and suspended in 50 mL growth
medium. The culture was incubated at 28°C
until the absorbance at 620 nm reached a
value of 1. The yeast culture was diluted to
an absorbance of 0.1 in fresh growth
medium, and 150 µL of this dilution was
seeded in a microtiter plate, already contain-
ing a concentration range of the test chemi-
cals. After an incubation of 24 hr at 28°C, 50
µL cycloheximide/CPRG solution was added
to each well. The solution was prepared by
adding 1 mL cycloheximide solution (20
mg/mL) and 200 µL CPRG solution (10
mg/L) to 4 mL minimal medium. To reveal
the β-galactosidase titer expressed during the
first incubation period, we incubated the
plate  overnight at 37°C. The next morning,
we checked the plates periodically for color
development and turbidity of the medium at
575 nm and 620 nm, respectively.
Calculations. We expressed β-galactosi-
dase activity as the ratio of the absorbance at
575 nm versus the absorbance at 620 nm.
Background values were subtracted from the
activity values. We generated dose–response
curves for doses (ordinate) versus activity
(abscissa). The data were fitted by a 4 para-
metric logistic model using the Marquardt-
Levenberg algorithm (Sigmaplot 4.0, SPSS
Inc., Chicago, Illinois, USA). Efficiency
(maximal response) and potency values
(median effective concentration; EC50) were
obtained by the parameters of the fitted
function.
Parameter min equals the baseline, and max
is the plateau of the curve designated as the
efficiency. Parameter EC50 gives the transi-
tion center and equals the potency, which is
the concentration that causes 50% effi-
ciency. The hillslope determines the slope of
the curve at the transition center.
In vitro system for culturing gut micro-
biota. We investigated the release of bioac-
tive isoflavones from a soygerm powder
(SOYLIFE, Soylife Nederland BV, Giessen,
The Netherlands), containing about 90
µmol conjugated isoflavones/g, by a complex
microbial ecosystem in batch experiments
using the gut microbiota cultured in a six-
stage culture system. This computer-con-
trolled reactor was developed to simulate the
bacterial communities found in certain parts
of the intestines. Each of the six reactors
contains the microbiota of a different part of
the human gastrointestinal tract, in order of
sequence (compartments 1–6): the stomach,
the duodenum, the small intestine, and the
ascending, transverse, and descending colon
(18). A detailed scheme of the reactor setup
is provided in Figure 2. The last 3 vessels
were inoculated with a pooled fecal sample,
and the microbial ecosystem was sustained
by the addition of a culture medium.
We determined the performance of the
microbial community based on plate counts
of selected indicator organisms and the fer-
mentative capacity (19).
Experimental setup. Enzymatic release of
isoflavones from soygerm powder was inves-
tigated using a 1 g/mL stock solution of
β-glycosidase [EC 3.2.1.21 from almonds
(Sigma)], which was prepared in 100 mM
bis[2-hydroxethyl] iminotris[hydrox-
ymethyl]methane [bis-Tris (pH 6.5)] and
kept at 4°C. An aliquot of 5 mL of this solu-
tion was transferred to a glass tube contain-
ing 25 mg soygerm powder in 5 mL 100
mM bis-Tris (pH 6.5). The suspension was
incubated at 37°C, and 3 mL samples were
withdrawn after 30, 60, and 120 min for
determining the β-glycosidase activity,
isoflavone concentration, and estrogenic
activity.
Generation of free isoflavones in the gut
was studied by means of the culture system.
We suspended 2.5 g/L soygerm powder in the
culture medium and withdrew 3 mL samples
after passage through vessel 1 and vessel 2.
The effect of the fermentation process, which
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Figure 1. Chemical structures of the test compounds.
17β-Estradiol Bisphenol A
Methoxychlor
Isoflavones
p,p´-Dichlorodiphenylthrichloroethane (p,p´-DDT)
is taking place in the large intestine, was
investigated in batch. Ten-milliliter samples
were withdrawn from compartment 4 of the
culture system and centrifuged for 10 min at
5,000 × g. The microbial pellet was washed
with an aliquot of sterile physiologic solution
and suspended in 10 mL of culture liquid
that passed vessel 2. We withdrew 3 mL sam-
ples from the test tubes after 30, 60, and 240
min. In all cases, we determined β-glycosidase
activity, isoflavone concentration, and estro-
genic activity. 
Determination of β-glycosidase activity.
Aliquots of samples (1 mL) were centrifuged
at 10,000 × g during 10 min. We pipetted
100 µL of the cell-free supernatant into a 96-
well plate, as well as 100 µL of a 5.0 mmol/L
solution of p-nitrophenyl-β-glycopyranoside,
prepared in a 0.1 mol/L phosphate buffer
(pH 6.5). The plates were incubated at 37°C,
and the absorbance at 405 nm was read after
30 min with a Biokinetics EL312e multi-well
reader (Bio-Tek Instruments Europe,
Spijkenisse, The Netherlands). The amount
of p-nitrophenol released was measured based
on a standard curve of p-nitrophenol. We
estimated the total protein concentration
using Bio-Rad protein assay reagent (Bio-
Rad, Nazareth Eke, Belgium), which is based
on the method of Lowry et al. (20). A bovine
albumin standard curve was created in paral-
lel with each protein determination. The
results were expressed in nanomoles p-nitro-
phenol released per milligram protein per
minute (21).
Extraction procedure. Samples (2 mL)
were extracted with 2 mL diethylether dur-
ing 30 min. The ether fraction was collected
after centrifugation at 5,000 × g during 5
min and subsequently vaporized at 37°C
under N2 atmosphere. The residue was dis-
solved in 2 mL absolute ethanol and filtered
(0.45 µm polypropylene filters; Alltech,
Laarne, Belgium) before transfer to glass
vials. Samples were stored at –20°C until
HPLC analysis and analysis of the estrogenic
activity.
HPLC analysis. We used a modified ver-
sion of the analytical HPLC method of
Wang and Murphy (22). The system con-
sisted of a Kontron liquid chromatograph
(BRS, Brussels, Belgium) with a Degasys
DG-310 system to degas the mobile phase, 3
Kontron 325 high-pressure pumps, a
Kontron MSI 660 injector with a 20-µL
loop, a Kontron DAD440 (diode array
detector), and 450 MT2/DAD software sys-
tem. The Genesis C18 column (4 µm, 15 cm
× 4.6 mm) was purchased from Jones
Chromatography (Mid Glamorgan, UK).
Isoflavones were eluted at 28°C using a linear
gradient of solvent A (0.1% acetic acid in
water) and solvent B (0.1% acetic acid in ace-
tonitrile). Five minutes after sample injec-
tion, the initial solvent ratio was 85% A/15%
B; this was linearly changed to 71% A/29%
B within 31 min. Forty minutes after injec-
tion, the percentage of B was again decreased
to 15%. After an additional column stabiliza-
tion of 5 min with the initial solvent ratio,
we analyzed the following sample. The flow
was controlled at 1.5 mL/min, and UV
detection was performed at 260 nm. Peak
areas were determined by electronic integra-
tion, and concentrations were calculated by
using the relation concentration–peak area
established for the pure isoflavones.
Statistical analysis. All values are
reported as mean ± SD. We performed
analysis of variance using SPSS 7.5 statistical
software (SPSS Inc., Chicago, IL, USA). A
p-value ≤ 0.05 was considered significant.
Results
Redesign of the recombinant yeast screen. In
the protocol of Routledge and Sumpter (16),
recombinant yeast cells are brought into con-
tact with the sample to be tested. At the start
of the experiment, the medium already con-
tains the β-galactosidase substrate CPRG.
Because the initial cell density in the RS assay
is low, yeast growth takes a lot of time, and
conversion of the CPRG starts after about 3
days of incubation. In the redesigned assay,
cells are brought into contact with the sample
in the absence of CPRG during 24 hr.
Subsequently, CPRG and cycloheximide are
added simultaneously. Because CPRG or its
β-galactosidase reaction product, chlorophe-
nol red, are weak estrogenic compounds (17),
the cycloheximide prohibits any further β-
galactosidase production so that possible
interference due to the presence of CPRG is
avoided. When using a higher initial cell den-
sity than in the RS assay (16), conversion of
the CPRG occurs after about 18 hr of incu-
bation. Figure 3 indicates that background
β-galactosidase activity for the negative con-
trols is significantly lower (p ≤ 0.05) in the
redesigned assay than in the the RS assay
(16). The higher activity in the RS assay was
caused by a significant increase of the
absorbance at 575 nm, indicating conversion
of the chromogenic substrate CPRG in the
absence of estrogenic compounds.
In a second series of experiments, sensitiv-
ity and reproducibility of the standard and
redesigned assay were assessed by measuring
the response to 17β-estradiol. The final con-
centrations of 17β-estradiol in the test ranged
from 3.48 × 10–12 M to 6.96 × 10–9 M. In the
case of the RS assay (16), the dose–response
curve was obtained after 3 days of incubation,
whereas with the redesigned assay the
dose–response curve was obtained after 24 hr
incubation with 17β-estradiol and an addi-
tional 18 hr incubation with the chromogenic
substrate CPRG (Figure 4). The 95% confi-
dence intervals for the EC50 value are 1.44 ×
10–10 to 10.78 × 10–10 M and 1.13 × 10–10 to
5.61 × 10–10 M for the RS assay (16) and the
redesigned assay, respectively. Analysis of vari-
ance revealed no significant differences
between the mean EC50 values. Subsequently,
we characterized the estrogenic activity of
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Figure 2. Schematic representation of a simulator of the human intestinal microbial ecosystem (SHIME).
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selected xenoestrogens (bisphenol A,
methoxychlor, and p,p´-DDT) and phytoe-
strogens (genistein, daidzein, glycitein). The
dose–response with the modified assay was
always higher than with the RS assay (16).
Figure 4 illustrates this for bisphenol A and
methoxychlor.
The dose–response curves for the test
compounds obtained with the redesigned
assay are shown in Figure 5. The β-galactosi-
dase activity was expressed as percent response
of the β-galactosidase activity elicited by the
highest concentration of 17β-estradiol (6.96
× 10–9 M), which was always analyzed in par-
allel with the test compounds, and which
arbitrarily equated with a response of 100%.
This data processing eliminated the variability
between experiments performed on different
occasions. With the redesigned assay, p,p´-
DDT exhibited moderate estrogenic activity,
in contrast with the RS assay (16) where p,p´-
DDT gave no response. The 95% confidence
intervals for EC50 values and efficiency of the
test compounds are summarized in Table 1.
Incubation of the recombinant yeast with
bisphenol A resulted in a 100% efficiency,
while the highest concentrations of methoxy-
chlor, p,p´-DDT, and genistein reached an
efficiency of 77, 11, and 65%, respectively.
Calculations of the estrogenic potencies of
bisphenol A, methoxychlor, p,p´-DDT, and
genistein using the EC50 values revealed that
the chemicals are 2,300, 25,000, 6,300, and
3,200 times weaker estrogens than 17β-estra-
diol. We detected no estrogenic activity for
daidzein and glycitein.
Release of bioactive phytoestrogens from
soygerm powder. During the incubation of
soygerm powder in bis-Tris (pH 6.5), the
β-glycosidase activity remained constant and
amounted to 4.32 ± 0.12 nmol p-nitrophe-
nol (per milligram protein per minute). The
results in Table 2 indicate that most of the
isoflavones were released after 30 min of
incubation [i.e., (133.7 ± 7.01) × 10–6
mol/L]. The concentration of genistein was
approximately 5 times lower than the con-
centration of daidzein or glycitein.
Estrogenic activity of extracts from 30-min
samples were determined with the modified
protocol. Estrogenic activity was calculated
as percent, compared to the expression of
6.96 × 10–9 mol/L 17β-estradiol, which was
equated with 100%. The estrogenic response
amounted to 34.7 ± 13.8% for 10-fold
diluted samples. The wells of the microtiter
plate contained about 8.9 × 10–7 mol/L
genistein, and this concentration corre-
sponds with the concentration of genistein
that caused 50% efficiency [i.e., a response
of 32.4% (Table 1)]. 
Soygerm powder (2.5 g/L) was suspended
in simulated intestinal microbiota ecosystem
culture medium and subjected to stomach
and small intestinal digestion by passage
through vessel 1 and vessel 2 of the culture
system. The suspensions did not exhibit β-
glycosidase activity. Neither the acidic condi-
tions of vessel 1 nor the presence of digestive
enzymes in vessel 2 released free isoflavones
(data not shown). Next, we studied the release
of bioactive isoflavones by the gut microbial
ecosystem. The β-glycosidase activity of the
final microbial suspension was 0.91 ± 0.42
nmol p-nitrophenol (per milligram protein
per minute). A total isoflavone concentration
of (128.3 ± 8.3) × 10–6 mol/L was generated
after 30 min incubation at 37°C and the
daidzein concentration accounted for 55%
(Table 3). The total concentration decreased
significantly (p ≤ 0.05) after 60 and 240 min
of incubation (Table 3).
The extracts from vessels 1 and 2 did not
exhibit estrogenic activity. Absorbance at
575 nm and 620 nm for the extract of vessel
1 was not significantly higher than for the
negative control. Extracts obtained after pas-
sage through vessel 2 significantly reduced
(p ≤ 0.05) the absorbance at 575 nm and
620 nm compared to the negative control.
The reduced absorbance at 620 nm indicates
an inhibition of the yeast growth (Table 4).
The 10-fold diluted extracts obtained from a
mixture of digested soygerm powder incu-
bated for 30 min with gut microbiota caused
a β-galactosidase activity higher than the β-
galactosidase activity expressed by 6.96 ×
10–9 mol/L 17β-estradiol, which was used as
a positive control (Table 4). The high β-
galactosidase activity of the extracts was due
mainly to the fact that the value of the
denominator (i.e., absorbance at 620 nm)
was significantly lower (p ≤ 0.05) than that
of the ethanol sample, indicating inhibition
of yeast growth. Despite the limited yeast
growth, there was a significant increase of
the absorbance at 575 nm (p ≤ 0.05) and a
color change from yellow to red compared to
the negative control, indicating the presence
of estrogenic activity (Table 4).
Discussion
Recently, public interest has been drawn to
endocrine modulators because they might
affect health in a negative (xenoestrogens) or
positive (phytoestrogens) way (9,23,24). In
vitro tests using yeast cells that harbor the
ERα gene and estrogen-responsive elements
coupled to a reporter system such as lacZ are
suited for quick and reliable screening and
sensitive analyses of estrogenic chemicals.
Routledge and Sumpter (16) investigated the
estrogenic potency of pure chemicals by
means of such a transformed yeast. Recently,
Beresford et al. (25) reported that, upon
longer incubation of this recombinant yeast,
the color of the blank wells changed slowly.
They contributed this increase of the 540-
nm absorbance values to the constitutive
expression of the reporter enzyme β-galac-
tosidase. Vanderperren et al. (17) found that
chlorophenol red is a weak estrogen. Hence,
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Figure 4. Dose response of the β-galactosidase
activity (absorbance at 575 nm/absorbance at 620
nm; mean ± SD) upon incubation of yeast with
17β-estradiol, bisphenol A, and methoxychlor.
n = 4.
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the estrogenic response in the assay might be
the result of the test compound and
CPRG/chlorophenol red. In view of the pos-
sibility that estrogenic compounds act syner-
gistically, we have redesigned the RS assay
(16) to eliminate this uncertainty.
The redesigned assay introduced here
comprises two steps. Contact between grow-
ing yeast and test compounds is allowed for 24
hr in growth medium. During this incubation,
estrogenic compounds trigger the expression
of β-galactosidase. The initial density in the
redesigned assay is adjusted to 0.1, which is
about 10 times higher than in the RS assay
(16). After 24 hr, a cycloheximide/CPRG
solution is added to each of the wells. The
cycloheximide inhibits peptidyltransferase,
which is responsible for peptide bond synthe-
sis during translation (26). This addition
stops the protein synthesis of the yeast, and
hence stops β-galactosidase production. The
β-galactosidase activity is quantified at 575
nm by the conversion of CPRG to chlorophe-
nol red during an overnight incubation at
37°C. In the RS assay (16), the reporter
enzyme is produced over a 3-day incubation
period at 32°C, which is consequently also
the temperature at which the β-galactosidase
enzyme activity is measured. In the
redesigned assay an end point measurement is
performed, which allows for the detection of
the β-galactosidase activity at its optimal tem-
perature of 37°C (27). Rather than measuring
optical density at 540 nm as in the RS assay
(16), we quantified the conversion of CPRG
to chlorophenol red at 575 nm, which is the
absorption maximum of chlorophenol red
(28). The modifications should allow more
rapid detection of estrogenic activity, without
possible interference of CPRG and/or its
cleavage product.
The results presented in Figure 3 indicate
that the background β-galactosidase activity
is significantly lower with the redesigned
assay compared to the RS assay (16). The
maximum β-galactosidase activity evoked by
17β-estradiol in the redesigned assay after 18
hr of incubation with CPRG was at least 2
times higher than the activity obtained with
the RS assay after 3 days of incubation
(Figure 4). EC50 values were not significantly
different between the two assays, and the
results are in agreement with values reported
by others. Arnold et al. (29) and Gaido et al.
(30) reported mean EC50 values of 1 × 10–10
M and 2.25 × 10–10 M, respectively.
The selected estrogenic compounds gen-
erally gave a lower signal in the RS assay (16)
than in the redesigned assay (Figure 4).
Estrogenic activity of p,p´-DDT was detected
with the redesigned assay (Figure 4).
Routledge and Sumpter (16) only tested o,p´-
DDT in their assay and found a weak estro-
genic response. Genistein was the only
phytoestrogen that induced a signal in both
assays. Our data on environmental estrogens
are in agreement with numerous reports
which have shown that these chemicals can
provoke an estrogen-like activity (Figure 4).
Gaido et al. (30) and Sohoni and Sumpter
(31) reported that bisphenol A has an effi-
ciency of 100% and is a 10,000-fold weaker
estrogen than 17β-estradiol. The activity of
methoxychlor is even lower, and this chemi-
cal induces an efficiency lower than 100%.
Coldham et al. (15) and Beresford et al. (25)
also observed this. Gaido et al. (30) esti-
mated the potency of methoxychlor to be
5,000,000-fold lower than that of 17β-estra-
diol. Although technical-grade DDT con-
tains 20% o,p´-DDT and up to 80%
p,p´-DDT (32), most of the studies on the
estrogenic activity of DDT have been done
with the o,p´-DDT isomer. Our results indi-
cate that the estrogenic potency of p,p´-
DDT is 6,300-fold lower than that of
17β-estradiol. Routledge and Sumpter (16)
and Gaido et al. (30) were not able to
demonstrate estrogenic activity of p,p´-DDT
in their in vitro assay. Chen et al. (32) inves-
tigated the estrogenic activity of DDT iso-
mers and metabolites in yeast and MCF-7
cells and reported that p,p´-DDT was able to
bind specifically to the human estrogen
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Table 1. 95% Confidence intervals (CI) for EC50 values and efficiencies of the test compounds detected
with the redesigned yeast assay (n = 4).
95% CI
Compound EC50 (mol/L) Efficiency (%)
17β-Estradiol 1.13 × 10–10–5.64 × 10–10 93.4–108.6
Bisphenol A 7.17 × 10–10–8.54 × 10–7 91.7–102.5
Methoxychlor 6.57 × 10–10–10.3 × 10–6 72.2–81.6
p,p´-DDT 1.01 × 10–6–3.27 × 10–6 7.8–15.2
Genistein 7.64 × 10–7–1.40 × 10–6 58.8–70.8
Daidzein ND ND
Glycitein ND ND
ND, no estrogenic activity was detected in the concentration range tested. 
Table 2. Concentration (mean ± SD) of isoflavones released from soygerm powder (90 µmol conjugated
isoflavones/g) after incubating 2.5 g/L soygerm powder in bis-Tris (50 mmol/L, pH 6.5) supplemented with
0.5 g/L β-glycosidase. 
Time Daidzein Genistein Glycitein Total
(min) (µmol/L) (µmol/L) (µmol/L) (µmol/L)
30 62.5 ± 5.5 8.9 ± 2.2 62.3 ± 3.9 133.7 ± 7.0
60 62.9 ± 10.6 18.1 ± 5.2 73.5 ± 21.8 154.5 ± 24.8
120 74.3 ± 5.9 15.5 ± 1.8 63.3 ± 7.0 153.1 ± 9.3
Suspensions were incubated at 37°C and sampled after 30, 60, and 120 min. n = 3 samples for each time point.
Table 3. Concentration (mean ± SD) of isoflavones released from soygerm powder (90 µmol conjugated
isoflavones/g) after incubating 2.5 g/L soygerm powder in a microbial suspension, as simulated in vessel 4
(ascending colon) of the simulator of the human intestinal microbial ecosystem (n = 3).
Time Daidzein Genistein Glycitein Total
(min) (µmol/L) (µmol/L) (µmol/L) (µmol/L)
30 70.2 ± 6.4 17.9 ± 4.6 40.2 ± 2.7 128.3 ± 8.3
60 54.5 ± 8.9 13.1 ± 3.8 31.0 ± 9.2 98.6 ± 13.3*
240 38.0 ± 3.0 6.5 ± 0.6 22.4 ± 2.4 66.9 ± 3.9*†
Suspensions were incubated at 37°C and sampled after 30, 60, and 240 min. n = 3 samples for each time point. 
*Significantly lower than the concentration observed after 30 min (p ≤ 0.05). †Significantly lower than the concentration
observed after 60 min (p ≤ 0.05).
Table 4. β-Galactosidase activity (expressed as the ratio of the absorbance at 575 nm versus the
absorbance at 620 nm) and absorbance data at 575 nm and 620 nm obtained with the redesigned yeast
screen assay.
β-Galactosidase activity Absorbance
Sample (A575/A620) 575 nm 620 nm
17β-Estradiol (6.96 × 10–9 M) 3.629 ± 0.270 2.221 ± 0.091 0.612 ± 0.038
Ethanol 1.143 ± 0.133 0.637 ± 0.055 0.589 ± 0.049
Vessel 1 1.232 ± 0.181 0.754 ± 0.075 0.612 ± 0.066
Vessel 2 1.247 ± 0.089 0.404 ± 0.022* 0.324 ± 0.015#
Vessel 4 5.335 ± 0.277 1.003 ± 0.041* 0.188 ± 0.006#
Values are mean ± SD; n = 3. We analyzed 10-fold diluted extracts from soygerm powder (2.5 g/L) after passage through
vessel 1 and vessel 2, and after 30 min of incubation with the microbial suspension of vessel 4 of the simulator of the
human intestinal microbial ecosystem.
*Significantly different from the ethanol sample, p ≤ 0.05. #Significantly lower than the absorbance obtained with the
sample from vessel 2.
receptor with approximately 1,000-fold
weaker affinity for the receptor than 17β-
estradiol. Daston et al. (24) reported in their
review on environmental estrogens that the
estrogenic potency of p,p´-DDT is 10,000-
fold lower than that of 17β-estradiol. This
value corresponds with our data.
Considerable attention has been focused
on the estrogenic effects of genistein
(14,16,33,34). However, much less is known
about the effect of daidzein and glycitein,
which are present in significant quantities in
soy products (35,36). To our knowledge, no
estrogenic responses of daidzein and glycitein
in yeast assays have been reported. We found
that genistein has about a 3,000-fold lower
potency than that of 17β-estradiol, and this
has also been confirmed by other studies
(16,33). Despite the structural resemblance
to genistein, we observed no estrogenic signal
for daidzein and glycitein in yeast assays.
Zhang et al. (37) estimated that the potency
of daidzein is 5-fold lower than genistein on
the basis of an experiment with mouse uter-
ine cytosolic estrogen receptors. Recently, the
three isoflavones were examined for their
estrogenic activity in the mouse uterine
enlargement assay (38). The data indicated
that daidzein and glycitein have weak estro-
genic activity, which is 10-fold lower than
that of genistein. 
The absence of estrogenic activity of
daidzein and glycitein in our experiments
might be due to the ability of yeast to excrete
these products actively by means of efflux
pumps. Two types of efflux pumps are
known for S. cerevisiae: the major facilitators
superfamily (39) and the ATP-binding cas-
sette-containing pumps (40). These proteins
are described as multidrug-resistant proteins
and are responsible for lowering the intracel-
lular content of antifungal agents. Each of
the proteins has different substrate speci-
ficity, and it has been emphasized that a
small structural difference of the compound
can result in a different expulsive capacity of
the cell (41). It is therefore plausible that the
subtle differences between the chemical
structures of the isoflavones are responsible
for daidzein and glycitein being actively
pumped out of the yeast cell, thereby pro-
hibiting the interaction of these compounds
with the estrogen receptor. Finally, such dis-
crepancy between estrogenic potencies
obtained with yeast-based assays and mam-
malian counterparts has been reported (13).
This indicates that there are restrictions with
each in vitro test and that only by using a
complementary suite of assays will it be pos-
sible to assess the biological effect of an
alleged estrogen (42).
Epidemiologic studies have shown that
the consumption of soybeans decreases the
risk of various diseases and conditions,
including cancer, osteoporosis, menopausal
symptoms, and coronary heart disease
(43–45). The isoflavones are the main mole-
cules responsible for these positive effects.
The isoflavones have been reported to have a
variety of biological activities, including
estrogenic activity (8). Isoflavones in soy
products exist primarily as biologically inac-
tive glycoside forms, which are poorly
resorbed in the intestines. Hence, a deconju-
gation step is essential to enhance resorption
and biological activity of the isoflavones.  We
found that β-glycosidase releases isoflavones
from soygerm powder. A high concentration
of isoflavones was released after 30 min of
incubation (Table 2). The estrogenic activity
of the extracts was confirmed by means of the
redesigned yeast assay, and this correlated
well with the concentration of genistein pre-
sent in the extracts. Next, we investigated
whether isoflavones were released under con-
ditions prevailing in the intestines. The β-
glycosides were neither hydrolyzed by acidic
conditions nor by pancreatic enzymes, which
is in agreement with the conclusion of
Dupont et al. (46). Subsequently, a suspen-
sion of digested soygerm powder was added
to a microbial suspension, which resembles
the microbiota present in the proximal part
of the large intestine. The concentration of
isoflavones recovered after 30 min of incuba-
tion was comparable to the concentration
after treatment with β-glycosidase (Table 3).
However, the concentration decreased signif-
icantly over time, which indicates ongoing
metabolism of the compounds (7,47).
Samples from the different digestive
stages were analyzed with redesigned yeast
assay. The extracts from vessel 1 did not dis-
play an estrogenic signal and did not interfere
with the yeast growth, in contrast to the
extracts from vessel 2, which significantly
inhibited yeast growth (Table 4). This inhibi-
tion may be due to the presence of bile salts
in the extracts. Simulated bile liquid contain-
ing 0.4 mmol/L bile salts were added in ves-
sel 2 of the culture system to simulate the in
vivo bile secretion. We recovered about 0.2
mmol/L bile salts in the extracts of vessel 2.
Bile salts occur in the intestine in a concen-
tration ranging from 0.1 to 5 mmol/L, and
they play an important role in solubilization
of dietary lipids. However, bile salts in this
concentration range also disrupt membrane
integrity and are toxic to bacteria, isolated
hepatocytes, and colonic mucosa (48–51).
The extracts obtained from samples of
digested soygerm powder incubated with a
microbial suspension exhibited a significantly
higher (p ≤ 0.05) absorbance at 575 nm
compared to the control with ethanol, which
points to estrogenic activity. The absorbance
at 620 nm was also significantly lower com-
pared to the sample with ethanol, which
reflects growth inhibition of the yeast (Table
4). The extract also contained about 0.2
mmol/L bile salts, which may have caused
the inhibition. The absorbance at 620 nm
was significantly lower than the samples
obtained from vessel 2. We therefore believe
that other compounds generated by bacterial
metabolism were extracted with diethylether
and caused an additional burden on the yeast
growth. We propose that yeast assays per-
form better than mammalian cell assays for
monitoring environmental samples (6,52).
In this study, we were able to extract free
isoflavones from a complex matrix and to
induce an estrogenic response with this crude
extract. Nevertheless, the presence of com-
pounds inhibiting yeast growth hindered the
straightforward interpretation of the data. It
is plausible that extracts contain toxic com-
pounds that completely mask the estrogenic
activity. Different types of biological assays
and analytical techniques will be imperative
to correctly assess estrogenic activity.
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